Johnson & Johnson SPINE,SPORTS & OTHER — Sales to Customers remained flat by 0.0% to $1.46B in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 0.7%, from $1.47B to $1.46B. Over 3 years (FY 2021 to FY 2024), SPINE,SPORTS & OTHER — Sales to Customers shows relatively stable performance with a 2.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption and successful commercial execution within the orthopedic and sports medicine segments. A decrease may signal increased competition, pricing pressure, or a decline in elective surgical procedures.
This metric represents the total revenue generated from the sale of products within the spine, sports medicine, and rela...
Comparable to revenue reported by other medical device manufacturers specializing in orthopedics, implants, and surgical instrumentation.
jnj_segment_spine_sports_other_sales_to_customers| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $5.40B | $5.80B | $5.89B | $5.85B |
| YoY Change | — | +7.4% | +1.6% | -0.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.